The costs of drug-eluting coronary stents among Medicare beneficiaries

American Heart Journal

Volumn 155, Issue 6, 2008, Pages 1097-1105

  Groeneveld, Peter W ^a,b,c   Matta, Mary Anne ^b   Greenhut, Alexis P ^b   Yang, Feifei ^b  

^a VETERANS AFFAIRS MEDICAL CENTER   (United States)

^b UNIVERSITY OF PENNSYLVANIA   (United States)

^c UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; ARTICLE; BARE METAL STENT; CONTROLLED STUDY; CORONARY STENT; COST BENEFIT ANALYSIS; COST EFFECTIVENESS ANALYSIS; DRUG ELUTING STENT; FEMALE; FOLLOW UP; HEALTH CARE COST; HOSPITALIZATION; HUMAN; MAJOR CLINICAL STUDY; MALE; MEDICARE; PERCUTANEOUS CORONARY INTERVENTION; PRIORITY JOURNAL;

AGED; AGED, 80 AND OVER; ANGIOPLASTY, TRANSLUMINAL, PERCUTANEOUS CORONARY; CORONARY ARTERY DISEASE; COST-BENEFIT ANALYSIS; DRUG-ELUTING STENTS; FEMALE; HEALTH CARE COSTS; HUMANS; MALE; MEDICARE; UNITED STATES;

EID: 44249127207     PISSN: 00028703     EISSN: 10976744     Source Type: Journal    
DOI: 10.1016/j.ahj.2008.01.012     Document Type: Article

References (22)

1. U.S. Food and Drug Administration. FDA approves drug-eluting stent for clogged heart arteries. Available online at. http://www.fda.gov/bbs/topics/NEWS/2003/NEW00896.html [Accessed April 24, 2007]
2. Moses J.W., Leon M.B., Popma J.J., et al. Sirolimus-eluting stents versus standard stents in patients with stenosis in a native coronary artery. N Engl J Med 349 (2003) 1315-1323
3. Park S.J., Shim W.H., Ho D.S., et al. A paclitaxel-eluting stent for the prevention of coronary restenosis. N Engl J Med 348 (2003) 1537-1545
4. Schofer J., Schluter M., Gershlick A.H., et al. Sirolimus-eluting stents for treatment of patients with long atherosclerotic lesions in small coronary arteries: double-blind, randomised controlled trial (E-SIRIUS). Lancet 362 (2003) 1093-1099
5. Bakhai A., Stone G.W., Mahoney E., et al. Cost effectiveness of paclitaxel-eluting stents for patients undergoing percutaneous coronary revascularization: results from the TAXUS-IV Trial. J Am Coll Cardiol 48 (2006) 253-261
6. Cohen D.J., Bakhai A., Shi C., et al. Cost-effectiveness of sirolimus-eluting stents for treatment of complex coronary stenoses: results from the Sirolimus-Eluting Balloon Expandable Stent in the Treatment of Patients With De Novo Native Coronary Artery Lesions (SIRIUS) trial. Circulation 110 (2004) 508-514
7. Kaiser C., Brunner-La Rocca H.P., Buser P.T., et al. Incremental cost-effectiveness of drug-eluting stents compared with a third-generation bare-metal stent in a real-world setting: randomised Basel Stent Kosten Effektivitats Trial (BASKET). Lancet 366 (2005) 921-929
8. vanHout B.A., Serruys P.W., Lemos P.A., et al. One year cost effectiveness of sirolimus eluting stents compared with bare metal stents in the treatment of single native de novo coronary lesions: an analysis from the RAVEL trial. Heart 91 (2005) 507-512
9. Gurel O. Drug-eluting stent market: $5 billion turning on a dime. Available online at. http://www.midwestbusiness.com/news/viewnews.asp?newsletterID=15086 [Accessed April 23, 2007]
10. Maisel W.H. Unanswered questions-drug-eluting stents and the risk of late thrombosis. N Engl J Med 356 (2007) 981-984
11. Rosenbaum P.R., and Rubin D.B. Constructing a control group using multivariate matched sampling methods that incorporate the propensity score. Am Stat 39 (1985) 33-38
12. Rubin D.B. Estimating causal effects from large data sets using propensity scores. Ann Intern Med 127 8 Pt 2 (1997) 757-763
13. Taira D.A., Seto T.B., Siegrist R., et al. Comparison of analytic approaches for the economic evaluation of new technologies alongside multicenter clinical trials. Am Heart J 145 (2003) 452-458
14. Basu A., Manning W.G., and Mullahy J. Comparing alternative models: log vs Cox proportional hazard?. Health Econ 13 (2004) 749-765
15. Manning W.G., and Mullahy J. Estimating log models: to transform or not to transform?. J Health Econ 20 (2001) 461-494
16. Manning W.G., Basu A., and Mullahy J. Generalized modeling approaches to risk adjustment of skewed outcomes data. J Health Econ 24 (2005) 465-488
17. Rubin D.B. The design versus the analysis of observational studies for causal effects: parallels with the design of randomized trials. Stat Med 26 (2007) 20-36
18. Groeneveld P.W., Suh J.J., and Matta M.A. The costs and quality-of-life outcomes of drug-eluting coronary stents: a systematic review. J Interv Cardiol 20 (2007) 1-9
19. Thomson Healthcare. Red book (2007), Thomson PDR, Montvale, NJ
20. Stone G.W., Moses J.W., Ellis S.G., et al. Safety and efficacy of sirolimus- and paclitaxel-eluting coronary stents. N Engl J Med 356 (2007) 998-1008
21. Smith Jr S.C., Feldman T.E., Hirshfeld Jr J.W., et al. ACC/AHA/SCAI 2005 guideline update for percutaneous coronary intervention. Circulation 113 (2006) e166-e286
22. Fuchs V.R. Economics, values, and health care reform. Am Econ Rev 86 (1996) 1-24